N-[2-(hydroxymethyl)-3-[2-[1-(2-hydroxypropanoyl)-3,6-dihydro-2H-pyridin-4-yl]-1H-pyrrolo[2,3-b]pyridin-4-yl]phenyl]isoindole-2-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-[2-(hydroxymethyl)-3-[2-[1-(2-hydroxypropanoyl)-3,6-dihydro-2H-pyridin-4-yl]-1H-pyrrolo[2,3-b]pyridin-4-yl]phenyl]isoindole-2-carboxamide
• 化学式: C₃₁H₂₉N₅O₄
• 分子量: 535.6
• InChiKey: ZPDQIUBGEAGTAN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  40
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  124
• 氢给体数：
  4
• 氢受体数：
  5

文献信息

• [EN] BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF<br/>[FR] COMPOSÉS BICYCLIQUES, COMPOSITIONS ET APPLICATIONS MÉDICINALES DE CEUX-CI
  申请人：ADVINUS THERAPEUTICS LTD

  公开号：WO2013157021A1

  公开（公告）日：2013-10-24

  The present disclosure relates to a class of substituted bicyclic compounds of formula (I), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, hydrates, N-oxides, co-crystals, pharmaceutically acceptable salts and pharmaceutical compositions containing them. The disclosure also relates to the process of preparation of compounds of Formula (I). These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of Bruton's tyrosine kinase (Btk), such as inflammatory and/or autoimmune disorder, cell proliferation, rheumatoid arthritis, psoriasis, psoriatic arthritis, transplant rejection, graft-versus-host disease, multiple sclerosis, inflammatory bowel disease, allergic diseases, asthma, type 1 diabetes, myasthenia gravis, hematopoetic disfunction, B-cell malignancies, systemic lupus, erythematosus or other disorders.

  本公开涉及一类式（I）的取代双环化合物，它们的互变异构体、多晶形态、立体异构体、前药、溶剂化物、水合物、N-氧化物、共晶体、药学上可接受的盐和含有它们的制药组合物。本公开还涉及制备式（I）化合物的方法。这些化合物在治疗、预防、预防、管理或辅助治疗与布鲁顿酪氨酸激酶（Btk）抑制有关的所有医疗状况方面有用，例如炎症和/或自身免疫性疾病、细胞增殖、类风湿性关节炎、银屑病、银屑病性关节炎、移植排斥、移植物抗宿主病、多发性硬化症、炎症性肠病、过敏性疾病、哮喘、1型糖尿病、重症肌无力、造血功能障碍、B细胞恶性肿瘤、系统性红斑狼疮或其他疾病。